Retrophin Mutual Funds | StatInvestor

Health Care & Life Sciences » Biotechnology | Retrophin Inc.

Retrophin Inc. | Mutual Funds

Mutual Funds that own Retrophin Inc.

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Delaware Small Cap Core Fund

1,085,700

2.69%

114,700

0.94%

05/31/2018

Vanguard Total Stock Market Index Fund

1,026,571

2.54%

07/31/2018

iShares Russell 2000 ETF

836,660

2.06%

-447

0.06%

09/06/2018

Fidelity Select Biotechnology Portfolio

797,045

1.97%

0.28%

07/31/2018

SPDR S&P Biotech ETF

755,282

1.87%

1,944

0.41%

09/06/2018

Prudential Jennison Health Sciences Fund

565,062

1.4%

0.7%

07/31/2018

CREF Stock Account

538,040

1.33%

37,315

0.01%

03/31/2018

Vanguard Extended Market Index Fund

525,003

1.3%

3,700

0.02%

07/31/2018

iShares Nasdaq Biotechnology ETF

460,588

1.13%

-6,027

0.15%

09/06/2018

HBM BioVentures Ltd.

433,952

1.07%

433,952

0.93%

12/31/2017

About Retrophin

View Profile

Address	3721 Valley Centre Drive San Diego California 92130 United States
Employees	-
Website	http://www.retrophin.com
Updated	07/08/2019
Retrophin, Inc. is a biopharmaceutical company, which engages in identifying, developing, and delivering therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.